Disease mongering: Expanding the boundaries of treatable disease

Evan Doran, D. Henry

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)

Abstract

Traditionally, the promotional activities of medical industries have been product specific. In recent years, however, there have been examples where companies have worked through partnerships, which have included clinicians, to expand the boundaries of treatable disorders. The main motivation appears to be to increase sales of commercial products. The term 'disease mongering' has been applied to these activities. Whereas some disease awareness programmes may bring benefits in the form of improved recognition and management of disorders, the presence of strong commercial interests probably distorts the traditional processes by which treatable diseases have been defined. This can result in individual patients being exposed to potential harms, with little expectation of benefit and will place an unwarranted burden on the publicly funded health-care system. None of this can happen without the collaboration of the medical profession that needs to be aware of the risks of becoming involved in commercially supported 'consensus' groups that are reviewing the definition and management of diseases.

Original languageEnglish
Pages (from-to)858-861
Number of pages4
JournalInternal Medicine Journal
Volume38
Issue number11
DOIs
Publication statusPublished - Nov 2008
Externally publishedYes

Fingerprint

Disease Management
Industry
Delivery of Health Care

Cite this

@article{0311c098ef8d4029ae7009dac37580ad,
title = "Disease mongering: Expanding the boundaries of treatable disease",
abstract = "Traditionally, the promotional activities of medical industries have been product specific. In recent years, however, there have been examples where companies have worked through partnerships, which have included clinicians, to expand the boundaries of treatable disorders. The main motivation appears to be to increase sales of commercial products. The term 'disease mongering' has been applied to these activities. Whereas some disease awareness programmes may bring benefits in the form of improved recognition and management of disorders, the presence of strong commercial interests probably distorts the traditional processes by which treatable diseases have been defined. This can result in individual patients being exposed to potential harms, with little expectation of benefit and will place an unwarranted burden on the publicly funded health-care system. None of this can happen without the collaboration of the medical profession that needs to be aware of the risks of becoming involved in commercially supported 'consensus' groups that are reviewing the definition and management of diseases.",
author = "Evan Doran and D. Henry",
year = "2008",
month = "11",
doi = "10.1111/j.1445-5994.2008.01814.x",
language = "English",
volume = "38",
pages = "858--861",
journal = "Australian and New Zealand Journal of Medicine",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "11",

}

Disease mongering : Expanding the boundaries of treatable disease. / Doran, Evan; Henry, D.

In: Internal Medicine Journal, Vol. 38, No. 11, 11.2008, p. 858-861.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Disease mongering

T2 - Expanding the boundaries of treatable disease

AU - Doran, Evan

AU - Henry, D.

PY - 2008/11

Y1 - 2008/11

N2 - Traditionally, the promotional activities of medical industries have been product specific. In recent years, however, there have been examples where companies have worked through partnerships, which have included clinicians, to expand the boundaries of treatable disorders. The main motivation appears to be to increase sales of commercial products. The term 'disease mongering' has been applied to these activities. Whereas some disease awareness programmes may bring benefits in the form of improved recognition and management of disorders, the presence of strong commercial interests probably distorts the traditional processes by which treatable diseases have been defined. This can result in individual patients being exposed to potential harms, with little expectation of benefit and will place an unwarranted burden on the publicly funded health-care system. None of this can happen without the collaboration of the medical profession that needs to be aware of the risks of becoming involved in commercially supported 'consensus' groups that are reviewing the definition and management of diseases.

AB - Traditionally, the promotional activities of medical industries have been product specific. In recent years, however, there have been examples where companies have worked through partnerships, which have included clinicians, to expand the boundaries of treatable disorders. The main motivation appears to be to increase sales of commercial products. The term 'disease mongering' has been applied to these activities. Whereas some disease awareness programmes may bring benefits in the form of improved recognition and management of disorders, the presence of strong commercial interests probably distorts the traditional processes by which treatable diseases have been defined. This can result in individual patients being exposed to potential harms, with little expectation of benefit and will place an unwarranted burden on the publicly funded health-care system. None of this can happen without the collaboration of the medical profession that needs to be aware of the risks of becoming involved in commercially supported 'consensus' groups that are reviewing the definition and management of diseases.

UR - http://www.scopus.com/inward/record.url?scp=57649158390&partnerID=8YFLogxK

U2 - 10.1111/j.1445-5994.2008.01814.x

DO - 10.1111/j.1445-5994.2008.01814.x

M3 - Article

VL - 38

SP - 858

EP - 861

JO - Australian and New Zealand Journal of Medicine

JF - Australian and New Zealand Journal of Medicine

SN - 1444-0903

IS - 11

ER -